Within the U.S. tax code, the treatment of research and development (R&D) expenditures differs sharply for domestic versus foreign activities. Domestic R&D can be expensed immediately under Section 174A—or amortized over at least 60 months—while foreign R&D must be capitalized and amortized over 15 years under Section 174, with no option for immediate expensing. This disparity, introduced by the One Big Beautiful Bill Act (OBBBA), has significant implications for investment timing, marginal project decisions, and the competitiveness of U.S. multinationals.
Timing and Marginal Investment
The distinction between expensing and amortizing is essentially one of timing. Using the Hall‑Jorgenson framework (Hall & Jorgenson, 1967), the user cost of capital (c) for a marginal project incorporates the present value of tax deductions, denoted (z). When (z = 1) (full expensing), the tax component of the cost of capital disappears, making the effective marginal tax rate on a breakeven investment zero. Conversely, amortizing deductions over 15 years reduces (z) below 1, raising the user cost of capital and creating a tax‑induced hurdle for marginal projects.
- Domestic R&D: Can avoid the higher user cost because firms may elect immediate expensing.
- Foreign R&D: Must amortize, pushing the user cost above the no‑tax baseline and discouraging marginal investment.
While inframarginal projects (those with clear net benefits) still generate taxable income regardless of the deduction schedule, the higher hurdle rate for marginal projects can lead to the abandonment of otherwise viable R&D initiatives.
Complementarity of Domestic and Foreign R&D
Domestic and foreign R&D are not substitutes; they typically complement each other. Foreign R&D often serves to adapt U.S.-developed products for local markets—addressing language, climate, infrastructure, or regulatory requirements—or to scale innovations through overseas research teams. Studies by Hufbauer, Moran, and Oldenski (PIIE) and commentary from the Information Technology and Innovation Foundation find that:
- Global R&D expenditures by U.S. multinationals create interdependent capabilities rather than merely shifting them abroad.
- Restricting foreign R&D would likely reduce total cross‑border knowledge production without delivering domestic gains.
Thus, penalizing foreign R&D risks diminishing overall U.S. innovation output.
Impact on Mergers and Acquisitions
Differential tax treatment also affects cross‑border M&A. When a U.S. firm acquires an R&D‑intensive foreign target, the target’s future R&D costs are amortized over 15 years for the U.S. buyer, whereas a foreign competitor can expense them immediately. This disparity lowers the after‑tax valuation for the U.S. bidder, reducing its competitiveness in acquisition auctions. The Semiconductor Industry Association has highlighted this disadvantage for U.S. chip firms, and similar effects are evident in pharmaceutical and other M&A‑heavy sectors.
Policy Implication
A neutral tax regime that treats R&D expenditures uniformly—regardless of location—would eliminate the timing‑based disincentive for foreign R&D, preserve the complementarity of global innovation activities, and improve the ability of U.S. firms to compete for foreign acquisitions. Aligning the tax treatment of domestic and foreign R&D could therefore enhance overall U.S. innovation and maintain the competitiveness of its multinational enterprises.
Source article: taxfoundation.org
